Clinical Trial Diversity: FDA Rejects Calls For Enrollment Mandates
Executive Summary
Requiring that underrepresented populations be enrolled based upon disease prevalence is only way to ensure adequate diversity, some stakeholders say; agency continues to prefer more flexible approach offered by guidance, and PhRMA says mandates would lengthen development timelines for new drugs.
You may also be interested in...
Should US FDA Refuse Approval If Women Under-Represented In Clinical Trials?
Idea suggested during 'Great Debate,' but agency official says no adlibbing is allowed in the regulations.
FDA Carrots And Sticks Are Best Way To Get Subgroup Data, Advocates Say
Stakeholders tell FDA it should force sponsors to recruit more diverse populations for its clinical trials by refusing to approve applications with inadequate data or expediting those with the necessary information.
FDA Acknowledges More Diverse Subgroup Data Needed In Trials
FDASIA-mandated report indicates some trials underrepresented some racial groups, but the agency says those subsets may not be the proper groupings in the era of personalized medicine.